{"task_id": "0ada25f125e453e3", "source": "Approach to Internal Medicine_ A Resource Book for Clinical Practice ( PDFDrive ).pdf (Part 418/464)", "text": "mol/L [16 mg/mL]\nHepatic Diseases in Pregnancy\n411\n\n--- Page 433 ---\nDIFFERENTIAL DIAGNOSIS (CONT\u2019D)\nACUTE FATTY LIVER OF PREGNANCY (T3, inci\ndence 0.008%)\nmay beassociated with preeclamp\nsia. Characterized by severe liver dysfunction\n(encephalopathy, hypoglycemia, coagulopathy) and\ncommonly jaundice. \"\" ALT, \"\" AST, \" bilirubin, \"\nWBC, \" PT, \" uric acid. U/S is often normal (micro\nvesicular fat on biopsy) and CT shows a lowdensity\nliver. May progress to acute hepatic failureandDIC in\n>75%. Increased maternal and fetal mortality\nPREECLAMPSIA/ECLAMPSIA (T2 3, incidence 5\n10%)\nseesectionunderpreeclampsia.Mayprogress\nto HELLP (4 12%), DIC (7%), jaundice (5 14%) later\nHELLP SYNDROME (T3, incidence 0.1%)\npre\neclampsia symptoms. \" ALT, \" AST, \" bilirubin, #\nplatelets, \" LDH. May progress to DIC (30%)\nOTHER CONDITIONS\ndrug induced hepatitis,\nascending cholangitis, acute cholecystitis, malig\nnancy, HBV, and HCV\nCLINICAL FEATURES\nHISTORY\njaundice,\npruritus,\nabdominal\npain,\nascites, swelling, encephalopathy, nausea and vomit\ning, headache, visual disturbances, fever, obstetrical\nhistory (current pregnancy course, previous births,\nprevious preeclampsia), past medical history (hyper\ntension, hepatitis, alcohol, IDU), and medications\nPHYSICAL\ncheck\nvitals\n(hypertension),\nedema\n(facial, limbs), heart (elevated JVP, S3, S4), hepatic\ntenderness, ascites, jaundice, and hyperreflexia\nINVESTIGATIONS\nBASIC\n\u0004\nLABS\nCBCD, peripheral smear, lytes, urea, Cr, spot\nurine for protein to creatinine ratio, AST, ALT, ALP\n(mild elevation could be from placenta), GGT, bilir\nubin, INR, bile acids (intrahepatic cholestasis), uric\nacid (acute fatty liver), LDH, fibrinogen (DIC), TSH\nINVESTIGATIONS (CONT\u2019D)\n\u0004\nMICROBIOLOGY\nHBV and HCV serology\n\u0004\nIMAGING\nU/S abd\nSPECIAL\n\u0004\nLIVER BIOPSY\nif not coagulopathic\nMANAGEMENT\nHYPEREMESIS\nGRAVIDARUM\nrule\nout\nmolar\npregnancy and hyperthyroidism. Supportive fluids.\nMetoclopramide,\ndimenhydrinate,\nand\ndiclectin\nacceptable. Consider ondansetron if refractory. Con\ntinuous metoclopramide infusion if severe\nINTRAHEPATIC CHOLESTASIS OF PREGNANCY\nursodeoxycholic acid or cholestyramine, increase\nfetal monitoring, consider early delivery as risk of\nfetal demise if high bile acids\nACUTE FATTY LIVER OF PREGNANCY\nvitamin K if\ncoagulopathic, early delivery\nHELLP\nanti hypertensive, MgSO4, early delivery\nHEPATITIS B OR C\nno proven treatment during\npregnancy (but risk of vertical transmission especially\nif co infection with HIV)\nSPECIFIC ENTITIES\nOTHER GI DISORDERS\n\u0004 GERD\nvery common during pregnancy. Treat\nments include lifestyle changes, antacids, raniti\ndine, PPIs, and metoclopramide\n\u0004\nCHOLECYSTITIS\npregnant women are at increased\nrisk due to hormonal changes. Medical manage\nment with IV fluids, NG, and opioids. Broad spec\ntrum antibiotics may be added for severe disease.\nCholecystectomy safest during 2nd trimester\nRelated Topics\nAcute Liver Failure (p. 128)\nDyspepsia (p. 113)\nInfectious Diseases in Pregnancy\nURINARY TRACT INFECTIONS\nASYMPTOMATIC\nBACTERIURIA\noccurring\nin\n2 7% of pregnancies, associated with pre term\nbirth, low birth weight, and perinatal mortality.\n30 40% will develop symptomatic UTI if untreated,\nand therefore should be treated (depending on cul\nture and local antibiotic resistance pattern, consider\namoxicillin clavulanate 500 mg PO BID \u00057 days,\nnitrofurantoin 100 mg PO BID \u00057 days [risk of hemo\nlytic anemia]). Avoid trimethoprim if alternatives\navailable. Follow up culture 1 week following treat\nment completion and then monthly until pregnancy\ncomplete\nURINARY TRACT INFECTIONS (CONT\u2019D)\nACUTE CYSTITIS\noccurring in 1% of pregnancies, with\ntreatment and follow up as asymptomatic bacteriuria\nPYELONEPHRITIS\noccurring in <1% of pregnan\ncies, complicated by septic shock and ARDS in 20%.\nIn patient treatment with IV antibiotics (cefazolin, cef\ntriaxone, or ampicillin plus gentamicin) until sympto\nmatic improvement and afebrile for 24 48 h then PO\nbased on drug sensitivities. Low dose suppressive anti\nbiotics (nitrofurantoin 50 100 mg PO qhs [risk of\nhemolytic anemia] or cephalexin 250 500 mg PO\nqhs) for remainder of pregnancy as recurrent pyelone\nphritis occurs in 6 8% of women without prophylaxis\n412\nInfectious Diseases in Pregnancy", "text_length": 4208, "metadata": {"source": "Approach to Internal Medicine_ A Resource Book for Clinical Practice ( PDFDrive ).pdf (Part 418/464)", "type": "chunk", "chunk_index": 417, "total_chunks": 464, "uploaded_by": "admin@admin.com", "upload_date": "2025-12-11T18:40:09.823446", "document_uuid": "fda2cab4-cdd9-4015-af24-46fd62c86d94", "filename": "Approach to Internal Medicine_ A Resource Book for Clinical Practice ( PDFDrive ).pdf", "category": "medical_pdf", "section": "body", "year": null, "outdated": false, "document_id": "fda2cab4-cdd9-4015-af24-46fd62c86d94"}, "created_at": "2025-12-11T18:40:09.824342", "status": "pending"}